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Parkinson’s Disease (PD) is a complex, chronic, progressive, and debilitating neurodegenerative disorder. Neither a cure nor
eﬀective long-term therapy exist and the lack of knowledge of the molecular mechanisms responsible for PD development is a
major impediment to therapeutic advances. The protein αSynuclein is a central component in PD pathogenesis yet its cellular
targets and mechanism of toxicity remains unknown. Mitochondrial dysfunction is also a common theme in PD patients and
this review explores the strong possibility that αSynuclein and mitochondrial dysfunction have an inter-relationship responsible
for underlying the disease pathology. Amplifying cycles of mitochondrial dysfunction and αSynuclein toxicity can be envisaged,
with either being the disease-initiating factor yet acting together during disease progression. Multiple potential mechanisms exist
in which mitochondrial dysfunction and αSynuclein could interact to exacerbate their neurodegenerative properties. Candidates
discussed within this review include autophagy, mitophagy, mitochondrial dynamics/fusion/ﬁssion, oxidative stress and reactive
oxygen species, endoplasmic reticulum stress, calcium, nitrosative stress and αSynuclein Oligomerization.
1.Introduction
Parkinson’s disease (PD) is a debilitating progressive neu-
rodegenerative disorder for which there is no cure or long-
term eﬀective therapy. Classical symptoms include move-
ment abnormalities such as postural instability and rigidity,
tremors, and bradykinesia but more recently nonmotor
symptoms have been ascribed to PD that include olfactory
deﬁcits, sleep disturbances, and gastrointestinal impairment.
Although the molecular mechanisms underlying the disease
are unknown, considerable evidence supports mitochondrial
dysfunction and alpha-Synuclein (αSynuclein) as two of the
major contributors to PD. This paper explores potential
interrelationships between these two factors that may con-
tribute to the initiation and/or progression of this disease.
2. Evidencefor DysfunctionalMitochondria
Pl a yingaC e ntralR o l einPD
Mitochondria are essential for neuronal function and sur-
vival. Energy-demanding neurons require large numbers
of functional mitochondria to provide most of their ATP
via oxidative phosphorylation (OXPHOS), a process where
electrons traversing the electron transport chain (com-
plexes I–IV) are coupled to proton pumping to establish
a mitochondrial membrane potential subsequently used to
synthesize ATP (complex V).
The involvement of mitochondrial dysfunction as a
causal factor of PD is well supported by observations in
patients [1, 2]. Impaired mitochondrial function is a pre-
dominant feature of PD with decreased activity in OXPHOS
complexes and/or high levels of mitochondrial DNA dele-
tions observed in PD-aﬀected neurons [2]. In sporadic PD,
altered or damaged mitochondrial proteins and impaired
OXPHOS function are commonly observed in the region of
thebrainmostdamaged,thesubstantianigra. Reducedlevels
of complex I subunits and impaired OXPHOS activity occur
[3–5], with oxidative damage, functional impairment, and
misassembly of complex I subunits found in PD brains [6].
Studies also observed mitochondrial complex I deﬁciency in
other tissues of PD patients including muscle and platelets
[7–9]. A stable decrease in complex I activity, increased ROS2 Parkinson’s Disease
production, proton leak, and decreased maximum OXPHOS
capacity also occur in PD cybrids (hybrid cells which contain
the nuclear genome from a control and the mitochondrial
genome from sporadic PD patients) [10, 11]. Furthermore,
expression proﬁling of neurons from preclinical PD patients
shows reduced mitochondrial biogenesis capacity [12]. All
of these features are consistent with the involvement of
OXPHOS dysfunction in sporadic PD, particularly with an
emphasis on complex I. Important complementary evidence
supporting thisdysfunctionasrelevanttoPDisderivedfrom
observations that complex I inhibitors cause Parkinsonism
symptoms and neurodegeneration [13]. Rats continually
exposed to rotenone, a complex I inhibitor, exhibit features
of PD. Importantly, these rotenone-induced features were
not due to the modest decrease in ATP levels resulting from
rotenone treatment as an equivalent ATP loss-induced by
2-deoxyglucose was not toxic [14]. Furthermore, MPTP-
derived MPP+, another complex I inhibitor, has been shown
to cause Parkinsonism in humans and rodents [15].
Mutations in mitochondrial-associated proteins DJ-1,
Parkin, and PINK1 also manifest themselves in familial
forms of PD with a common theme involving defects in
mitochondrial homeostasis, dynamics, and quality control.
Mitochondria are the primary producers of reactive oxy-
gen species (ROS), a byproduct of electron transfer in
OXPHOS. Electrons may be leaked to oxygen, resulting in
superoxide and other reactive oxygen species. A number
of enzymatic antioxidants including superoxide dismutase
(SOD1 cytosolic and SOD2 mitochondrial), catalase, and
glutathione peroxidases exist to detoxify these harmful
species [16]. Impairment of these antioxidant systems or
an excess ROS generation results in oxidative stress that is
well associated with PD. DJ-1 is a mitochondrial chaperone
ascribed to providing neuroprotection against oxidative
stress, and mutations in DJ-1 have been found to cause a
form of autosomal recessive early-onset Parkinson’s disease.
Its role remains unclear, yet DJ-1 is reported to interact with
complexIandmayplayaroleinthemaintenanceofcomplex
Ia c t i v i t y[ 17]. This is consistent with its reduced expression,
enhancingthetoxicitycausedbycomplexIinhibitorsbutnot
from agents that inhibit complexes II–V [18].
Parkin and PINK1. Mitochondria are remarkably dynamic
organelles that constantly undergo a complex cycle of fusion
and ﬁssion thought to be a crucial quality control system
for the homeostasis of the mitochondrial network [19].
Fusion of mitochondria into a dynamic network allows the
distributionandrepairofmitochondrialproteins,mitochon-
drial genomic DNA, and lipids, whereas ﬁssion eﬀectively
isolates defective mitochondria from the network, which can
then undergo a form of autophagic degradation, termed
mitophagy [20]. Loss-of-function mutations in either Parkin
or PINK1 can result in familial recessive forms of Parkinson’s
disease. PINK1 and Parkin act in concert to utilise the
mitochondrial ﬁssion-fusion cycle to initiate the segregation
and removal of irreversibly damaged/dysfunctional mito-
chondria with reduced mitochondrial membrane potential.
Suchmitochondriaaccumulatetheputativeserine/threonine
kinase PINK1 on the outer mitochondrial membrane which
in turn recruits the cytosolic ubiquitin ligase Parkin. Parkin-
dependent ubiquitination/degradation of mitochondrially
associated Miro results in mitochondria losing their attach-
ment to microtubules and arresting their movement [21].
Fusion of the damaged mitochondria into the network is
also prevented while the recruitment of autophagy compo-
nents initiates the formation of a phagophore around the
mitochondria prior to lysosomal delivery. That Parkin and
PINK represent familial forms of Parkinson’s disease clearly
demonstrates the neuroprotective importance of eﬃciently
disposing of damaged and dysfunctional mitochondria.
3. The Central Role of αSynuclein in PD
Although the molecular mechanisms responsible for the
disease are unknown, considerable evidence suggests the
involvement of αSynuclein as a central component of PD.
αSynuclein is the major structuralconstituent of cytoplasmic
inclusion bodies (Lewy bodies) and neurites (Lewy neurites)
that are characteristic of both familial and sporadic PD
cases. Allele duplication or triplication of the wild-type
αSynuclein gene (SNCA) results in autosomal dominant PD
with a severity proportional to the degree of αSynuclein
overexpression [22], and missense mutations in αSynuclein
(e.g., A30P, A53T) are linked to dominantly inherited forms
of PD [23]. Most signiﬁcantly, genome wide association
studiesinmultiplepopulationsdisplayedthatvariationatthe
SNCA locus is robustly associated with sporadic PD [24–28].
αSynuclein is a small cytosolic protein capable of binding
synaptic vesicles although its N-terminal lipid binding
domain appears capable of binding to other membranes
[29]. Its native function remains unclear and αSynuclein
knockout mice show only a very mild phenotype [30]. With
its dose-dependency and dominant inheritance pattern,
αSynuclein is widely viewed as acting in a toxic manner with
oligomeric species considered to mediate this toxicity instead
of monomeric or the ﬁbrillar forms found in Lewy bodies
[31, 32]. Overexpressed and/or mutant αSynuclein has been
ascribed to interfere with a number of intracellular processes
that include membrane traﬃcking [33], autophagy [34],
proteasomal degradation [35] and a range of mitochondrial
functions [36].
4. AnInterrelationshipbetween αSynuclein
andMitochondrialDysfunction?
Recently αSynuclein has been reported to interact with
mitochondria, raising the intriguing possibility that these
two central components of PD might have a synergis-
tic inter-relationship that contributes towards the com-
plexities of PD. Additional evidence supporting such an
interaction includes the following: (i) mice overexpressing
αSynuclein treated with MPTP have signiﬁcantly greater
mitochondrial abnormalities than when treated with saline
or wild-type mice treated with MPTP [37]; (ii) small
molecules were identiﬁed that suppressed αSynuclein tox-
icity, and surprisingly they were found to also suppressParkinson’s Disease 3
the toxicity of a rotenone (complex I inhibitor) PD model
[38].
Possiblemechanismsofsuchaninterrelationshipinclude
αSynuclein directly or indirectly impairing mitochondrial
function, mitochondrial dysfunction exacerbating αSynu-
cleintoxicity,or,perhapsmorelikely,αSynucleintoxicityand
mitochondrial dysfunction enhancing each other in a self-
amplifying cycle.
5.PotentialMechanismsby WhichαSynuclein
CouldInduceMitochondrialDysfunction
5.1. Does αSynuclein Physically Interact with Mitochondria?
αSynuclein has been detected in mitochondrial fractions
from a range of model systems including cultured cells over-
expressing αSynuclein [39] or mice brain homogenates [40].
Numerous immunohistochemistry studies have also iden-
tiﬁed αSynuclein association with mitochondria although
some show association in regions of the brain not aﬀected
by PD. The questions regarding these ﬁndings have been as
follows (i) does this indicate speciﬁc binding of αSynuclein
to mitochondria or instead reﬂect a general membrane
association of αSynuclein via its lipid binding domain, (ii)
is αSynuclein associated with the cytosolic face of the outer
mitochondrial membrane or has it been imported into the
mitochondria, and (iii) does this mitochondrial association
of αSynuclein contribute to the disease?
In vitro, αSynuclein appears to bind preferentially to
highly curved, anionic lipid surfaces [41]. Mitochondria
are resplendent in both curvature and anionic lipids such
as cardiolipin. Indeed, liposomes derived from mitochon-
drial membranes, as well as liposomes rich in cardi-
olipin, bind αSynuclein while liposomes containing neu-
tral lipids do not. Further, αSynuclein binding to cardi-
olipin is sensitive to competition from other cardiolipin-
binding molecules, suggesting lipid-binding speciﬁcity
[42].
Beyond simply binding to the surface of mitochondria,
αSynuclein appears capable of being translocated across
the outer mitochondrial membrane, likely by the outer
mitochondrial translocation (TOM) machinery. Isolated
mitochondria confer protease protection to recombinant
αSynuclein, and this protection was lost in the pres-
ence of antibodies against TOM40. Additionally, both the
OXPHOS uncoupler CCCP and the ATP synthase inhibitor
oligomycin severely decreased αSynuclein import [43]. A
crypticmitochondrialtargetingsequencehasbeensuggested,
and αSynuclein shares its lysine-rich N-terminus with a
variety of nuclear-encoded mitochondrial proteins. These
positive N-termini remain natively unfolded, like αSynuclein
itself, potentially for recognition by mitochondrial import
machinery [43, 44]. Although deletion of the highly positive
N-terminus prevents the observed protease protection [43],
it also removes the lysine-rich region that has been shown
to confer speciﬁcity towards anionic lipids [41]. Therefore,
it remains unclear whether the N-terminus leads to mito-
chondrial accumulation through direct membrane binding
or through import machinery targeting.
αSynuclein speciﬁc localisation within mitochondria is
less clear. Some immune-EM experiments show αSynuclein
localised to the intermembrane space [43, 45], while others
showdistributionthroughoutboththeintermembranespace
and the matrix [46, 47]. The eﬀort to elucidate αSynuclein
location within mitochondria is complicated by the fact that
translocation of αSynuclein to the matrix may, in fact, be a
sign of mitochondrial dysfunction. It has been reported that
cells transfected to overexpress αSynuclein had signiﬁcant
localisationof αSynucleintothemitochondrial matrix,while
vector-control-transfected cells showed only intermembrane
localisation of endogenous αSynuclein. Mitochondria from
αSynuclein overexpressing cells also showed signiﬁcant mor-
phological changes such as disorganised cristae, swelling
of the intermembrane space, and gross fragmentation of
both membranes [46]. It is possible that relocalisation of
αSynuclein to the matrix may occur once signiﬁcant damage
has been done to the mitochondria, or once αSynuclein
concentrations reach a threshold level. It is also possible
that an unknown αSynuclein binding partner may promote
or hinder translocation to the matrix, leading to disparate
results across multiple disease models.
5.2. αSynuclein Translocates into Mitochondria and Impairs
OXPHOS. The decrease in complex I activity, observed in
patient brain samples [43, 48], transfected cell lines [43, 49],
puriﬁed mitochondria [46], and transgenic animals [49, 50],
is surprising in its speciﬁcity: none of the other OXPHOS
complexes appear to be consistently aﬀected by increased
levels of αSynuclein [43, 48–50]. Perhaps most convincingly,
complex I activity was negatively correlated with strong
signiﬁcance, with the amount of αSynuclein found within
mitochondria isolated from patient brain samples [43].
Interestingly, the inhibition of complex I was only observed
within the substantia nigra (SN),and no correlation between
αSynuclein levels and complex I activity was observed in the
cerebellum. However, mitochondrial αSynuclein expression
was signiﬁcantly lower in the cerebellum (roughly tenfold
less) and perhaps had not reached toxic threshold levels
[43]. This data suggests that αSynuclein could be integral
to the observed loss of complex I activity, but that reaching
toxicintramitochondriallevelsmayrequireadditionaltissue-
speciﬁc factors that inﬂuence import of the protein.
The intermembrane space localisation of αSynuclein
leads to the possibility of a direct interaction between
αSynuclein and complex I. Indeed, in patient brain samples
examined by blue native PAGE αSynuclein was found to
localise to bands representing complex I. Furthermore, in
patient samples and transfected cultured cells, but not
healthy controls or transfected cells grown for a shorter
time, multiple smaller bands positive for a complex I subunit
were observed, suggesting a deﬁciency in the assembly of
the complex I holoenzyme [43]. It is important to note
that while other researchers have noted an impairment in
complex I activity in transgenic mice with no impairment of
assembly, these researchers did not examine cross-reactivity
to αSynuclein [49], and therefore a direct interaction cannot
be eliminated in these mice models of PD.4 Parkinson’s Disease
What form of αSynuclein might be responsible for the
observedcomplexIinhibition?Inductionofhigh-molecular-
weight αSynuclein oligomers in cultured dopaminergic cells
via exposure to 18:3 polyunsaturated fat [51] did not
inhibit complex I activity in these cells [49]. Additionally,
transgenic mice expressing the A53T mutant form of
αSynuclein showed no correlation between levels of aggre-
gated αSynuclein, measured by immunoblot, and complex 1
activity [49]. It is possible that monomeric αSynuclein and
oligomeric αSynuclein are toxic to cells in disparate ways, the
former hampering OXPHOS function while the latter leads
to deﬁciencies in transport, autophagy, and protein degra-
dation. Certainly, impairment of the OXPHOS could lead to
dissipated membrane potential and lower levels of oxidative
phosphorylation. This could alter the available ATP, exacer-
bating stresses placed on the cell by oligomeric inclusions of
αSynuclein. These cellular stresses could, in turn, increase
mitochondrial stress via Ca2+ intake, leading to a cycle of
increasing dysfunction in various subcellular locations.
As with determining mitochondrial localisation of αSy-
nuclein, there are conﬂicting reports as to how αSynuclein
aﬀects membrane potential and ATP production. In vitro,
recombinant αSynuclein lowers membrane potential and
ATP production in isolated mitochondria without any
discernableeﬀectsontheactivityoftheOXPHOScomplexes.
αSynuclein concentrations as low as double endogenous
concentrations were suﬃcient to observe loss of mem-
brane potential and ATP production [52]. In vivo,l o s s
of membrane potential, visualised by TMRM ﬂuorescence,
and O2 consumption were both observed in transfected
cells overexpressing αSynuclein. Consistent with the severe
pathology associated with A53T mutations in αSynuclein,
the eﬀects on membrane potential and O2 consumption
were more severe when the mutant protein was expressed
[53]. However, other mitochondrial pathologies, such as
increased fragmentation and decreased rate of fusion, have
been reported in the absence of impairment of respiration
or loss of membrane potential [45]. This raises the ques-
tion: could αSynuclein be acting at multiple locations on
and within mitochondria to inﬂuence diﬀerent functions
through disparate physical interactions? or is there a central
factor inﬂuenced by αSynuclein that, in turn, inﬂuences a
variety of mitochondrial functions?
One crucial family of molecules within the mitochon-
dria are the cardiolipin family of phospholipids. These
fatty acids are unusual in their bicyclic nature, yielding a
phospholipid with four, rather than two, fatty acid tails.
Cardiolipins are implicated in a variety of critical processes
such as mitochondrial fusion, protein complex stability, and
metabolite transport [54]. Loss of cardiolipin in C. elegans
(via knockout of a gene required for cardiolipin synthesis)
leads to the loss of mitochondrial membrane potential and
distortion of cristae within germ cells [55], and similar
resultswereobservedinS.cerevisiae[56].Evenmoredirectly,
invitroexperimentsonpuriﬁedOXPHOScomplexesshowed
complex I to be dependent on cardiolipin for proper electron
transfer [57]. In summary, cardiolipin is integral to many
mitochondrial processes found to be deﬁcient in models of
PD.
Cardiolipin therefore proves to be an interesting target
for αSynuclein toxicity. Its known involvement in PD
impaired processes, as well as observed speciﬁc binding
of cardiolipin by αSynuclein points towards an important
molecular interaction. Somewhat surprisingly, αSynuclein-
knockoutmiceshowadecreaseinmitochondrialcardiolipin,
cardiolipin precursors, and complex I-/III-linked activity
(electron transfer from complex I to complex III) yet no
impairment of any single complex. Due to the mitochon-
drial localisation of cardiolipin synthesis and the ability of
αSynucleintobindcardiolipinanditsprecursors,theauthors
suggest that endogenous αSynuclein may in fact help target
lipids to the mitochondria for use in other biosynthetic
pathways [58]. Conceivably, tight binding of cardiolipin by
αSynuclein could prevent proper function. This impairment
would be a proportional interaction, where higher levels of
αSynuclein would deplete the bioavailable cardiolipin pool
in a one to one ratio, consistent with the observation that
complex I inhibition is proportional to αSynuclein levels
[43]. Unfortunately, there is a lack of literature on the eﬀects
of high αSynuclein levels on cardiolipin. However, due to
the well-documented interactions between cardiolipin and
αSynuclein, and the similarity between pathologies caused
by loss of cardiolipin and overexpression of αSynuclein,
further investigation into their interrelationship seems well
warranted.
5.3. αSynuclein Perturbs the Mitochondrial Fission-Fusion
Cycle. αSynuclein lipid-binding capacity and proposed
speciﬁcity for mitochondrial membranes resulted in several
recent studies focused on the involvement of αSynuclein in
inhibiting the crucial and delicately balanced mitochondrial
ﬁssion-fusion cycle [59]. Mitochondrial fusion is an essential
process of mitochondrial dynamics, involved in the mainte-
nance of mitochondrial homeostasis. Mitochondrial fusion
maintains proper OXPHOS functionality by promoting the
sharing of integral proteins across the mitochondrial popu-
lation. Fusion is also required for the proper segregation and
inheritance of mitochondrial DNA. Mitochondrial fusion
enables the exchange of contents between mitochondria and
allows damaged mitochondria to acquire components from
healthy mitochondria, diluting damage thatwould otherwise
require disposal of an individual mitochondrion [20].
Elevated αSynuclein expression in cultured cells resulted
in αSynuclein binding mitochondria and mitochondrial
fragmentation whereas siRNA-mediated knockdown of
αSynuclein resulted in elongated mitochondria [45]. Such
observations could be due to αSynuclein either inhibiting
mitochondrial fusion or enhancing mitochondrial ﬁssion
or alternatively impairing OXPHOS that in turn results in
fragmentation.
5.3.1. αSynuclein Inhibits Mitochondrial Fusion. Evidence
supporting αSynuclein as an inhibitor of mitochondrial
fusion utilised in vitro fusion experiments where fusion
of small artiﬁcial unilamellar vesicles was suppressed by
recombinant αSynuclein in a dose-dependent manner [45].
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also found to severely decrease mitochondrial fusion events.
Cells expressing either GFP- or DsRed-tagged mitochondria
were artiﬁcially fused via PEG treatment and mitochondrial
fusion monitored by DsRed colocalization [45]. Promoting
lengthened,tubularmitochondriaviatheelevatedexpression
of fusion-promoting proteins Mfn1, Mfn2 and Opa1, or
alternatively via the knockdown of the ﬁssion-promoting
protein Drp1 was found to reduce the proportion of frag-
mented mitochondria in cells challenged with αSynuclein.
However, the overexpression of fusion proteins was not
suﬃcient to rescue mitochondrial morphology. Additionally
both Drp1 knockdowns and cells expressing dominant-
negative Drp1 still showed decreased mitochondrial length
uponαSynucleinexpression.Thisledtheauthorstoconclude
that αSynuclein inhibition of fusion acted independently
of mitochondrial fusion and ﬁssion proteins [45, 47].
Even endogenous levels of αSynuclein appear to impede
mitochondrial fusion. Having induced mitochondrial frag-
mentation with CCCP, an ionophore which dissipates
mitochondrial membrane potential, the fusion-dependent
morphologic recovery after CCCP washout was slower in
cells expressing endogenous αSynuclein levels compared to
αSynuclein siRNA knockdown cells [45]. αSynuclein was
proposed to function as a stabiliser of lipid packing defects
in highly curved membranes. Essentially acting as a bandage,
αSynuclein “patches” itself on the membrane at an area of
high curvature, where a fusion event would normally occur,
eﬀectively halting the fusion process [45]. This model agrees
with data showing αSynuclein preferentially binding to areas
of high membrane curvature [41]. Further supporting the
possibilityofαSynucleinstericallyhinderingfusionisthefact
that cardiolipin, a strong binding partner for αSynuclein, is
often enriched in fusion event zones.
5.3.2. αSynuclein Induces Mitochondrial Fragmentation. In
contrast, other studies have found that αSynuclein does
not impair mitochondrial fusion but instead is capable of
enhancing mitochondrial fragmentation [47]. The mito-
chondrial ﬁssion promoting properties of αSynuclein were
independent of the native ﬁssion machinery and required
the membrane-binding N-terminus of αSynuclein [47],
suggesting that αSynuclein may fragment mitochondria by
directly binding and disrupting mitochondrial membranes.
In vitro, cardiolipin-containing vesicles, but not vesicles
lacking cardiolipin, were found to decrease in size when
exposed to recombinant αSynuclein [47]. Further analysis
supported the assertion that oligomeric αSynuclein was
responsible for the ﬁssion observed which, given that
monomeric αSynuclein can also bind membranes, suggests
binding alone is insuﬃcient [47].
It is clear that αSynuclein causes mitochondrial fragmen-
tation, but it is unclear if this is a result of increased ﬁssion,
impaired fusion or a combination of both.
5.4. αSynuclein Inhibition of Autophagy and Mitophagy.
Mitophagy is a specialised form of autophagy to remove
and dispose of dysfunctional mitochondria. Mitophagy uses
componentnsoftheautophagymachinerytoencapsulatethe
mitochondrion in a phagophore membrane and deliver it
to the lysosome for degradation. The ability of αSynuclein
to impair macroautophagy [60] would have the potential
to impair mitophagy, thereby causing an accumulation of
dysfunctional and potentially ROS producing mitochondria.
Interestingly,neithertheαSynucleinmutantsA30PnorA53T
were found to impair macroautophagy [60].
In contrast to αSynuclein impairing autophagy, Choubey
et al. propose that expression of αSynuclein mutant A53T
might in fact induce detrimental supraphysiological lev-
els of mitophagy/autophagy. The elevated expression of
mutant A53T αS y n u c l e i ni np r i m a r yn e u r o n sr e s u l t e di n
extensive mitochondrial loss resulting in a bioenergetic
deﬁcit [61]. The mitochondrial loss required mitochondrial
fragmentation, Parkin, and the autophagy protein Beclin,
suggesting mitophagy was responsible. The authors pro-
posed that A53T αSynuclein had caused an overactivation
of autophagy that resulted in the excessive disposal of
functional polarised mitochondria. This is consistent with
EM analysis of mouse midbrain dopaminergic neurons
expressing high levels of mutant A53T αSynuclein which
displayed an increase in the proportion of mitochondria
sequestered in double-membraned structures, presumably
autophagosomes [50]. However, an alternative possibility
is that αSynuclein impaired the later membrane traﬃcking
stages of autophagy/mitophagy involving fusion with lyso-
somes, which would cause an accumulation of autophago-
somes. Choubey et al. utilised a pH-sensitive dual-ﬂuor LC3
construct to explore the rate of autophagosome delivery
to lysosomes, and found no change in the presence of
αSynuclein [61]. However, multivesicular bodies (MVBs),
another destination for autophagosomes [62], are also acidic
[63] and delivery to an MVB would likely cause the LC3
construct to behave similarly, as if delivered to a lysosome.
Therefore, a traﬃcking impairment to lysosomes cannot be
dismissed.Further,itisuncleariftheinductionofmitophagy
is initiated at mitochondria themselves, or whether the
observed increase in mitophagy is a secondary eﬀect of
general upregulation of macroautophagy. Knockdowns of
both Parkin, crucial for induction of mitophagy at the
mitochondrial level, and Beclin, involved in assembly of
the autophagophore, lead to similar increases in survival of
αSynuclein-challenged cultured neurons.
5.5. αSynuclein-Induced Endoplasmic Reticulum (ER) Stress
Impairs Mitochondrial Function. The endoplasmic retic-
ulum (ER) is a multifunctional organelle essential for
cellular processes including lipid synthesis, regulation of
calcium homeostasis, and biosynthesis of proteins destined
for intracellular organelles, the cell surface, or secretion
[64]. Intriguingly the ER is intimately connected, both
physically and functionally, to the mitochondria allowing
the signalling and exchange of metabolites between these
two organelles [65], including phospholipid exchange for
biosynthesis and controlled release of Ca2+ from the ER to
themitochondria[66,67].Toaccomplishthis,amultiprotein
complex tethers ER membranes to mitochondrial outer
membranes in close association in a structure termed6 Parkinson’s Disease
MAM (mitochondria-associated ER membrane) [65, 66].
Recently the ER has also been shown to provide a role in
mitochondrial ﬁssion. In both yeast and mammalian ER-
mitochondrial contact sites ER tubules constrict mitochon-
drial tubules to a size suﬃciently small enough for the
DRP1 ring-like structure to perform its scission function
during mitochondrial ﬁssion [68]. The close physical and
functional association between the ER and mitochondria
provides the opportunity for stress or dysfunction in one
organelle to potentially disrupt homeostasis in the other
organelle. ER stress has been detected in dopaminergic
neurons of the substantia nigra bearing αSynuclein inclu-
sions in the brain of patients aﬀected by PD, indicating
t h a tE Rs t r e s si si n v o l v e di ns p o r a d i cP D[ 69]. Further-
more the ER stress observed closely correlated with the
accumulation and aggregation of αSynuclein [69]. Elevated
αSynuclein levels have been found to block ER to Golgi
membrane traﬃcking [33, 70]a n dc a u s eE Rs t r e s s[ 33],
raising the possibility that αSynuclein-induced ER stress
might play a role in precipitating mitochondrial stress [71,
72].
The ER is the main cellular calcium store, but under
conditions of prolonged ER stress, the ER releases calcium
into the cytosol, resulting in the transfer of calcium to
mitochondria which eﬀectively buﬀers cytosolic calcium
levels [73]. However, the resulting mitochondrial calcium
levels, if too high, can lead to a depolarisation of mito-
chondrial membrane potential, decreased ATP synthesis,
and ultimately the opening of the permeability transition
pore leading to mitochondrial swelling and eventually death
[73]. Interestingly, MAM sites appear to be dependent
on MFN2 (a mitochondrial fusion promoting protein), as
loss of this protein results in increased ER-mitochondrial
distances and ablation of ER-mitochondrial calcium transfer
[73]. As discussed earlier, MFN2 can suppress αSynuclein-
induced mitochondrial morphological changes (though not
fully reverse them) in cultured cells [45]a sw e l la sd e c r e a s e
autophagosome-associated mitochondria in neurons chal-
lenged with the A53T mutant of αSynuclein [61]. The ability
of MFN2 to regulate ER-mitochondrial distance and mediate
calcium uptake could explain the cytotoxicity in MFN2
overexpressing cultured neurons reported by Choubey et al.
due to the mitotoxic eﬀect of chronic high mitochondrial
calcium levels [61]. Further, ER structure is dependent on
MFN2, indicating a reciprocal relationship between the ER
and mitochondria [73] and reinforcing the possibility of an
escalating cycle of toxicity between the two organelles.
ER stress might also negatively impact mitochondria by
perturbing lipid biosynthesis. The synthesis of lipids such
as cardiolipin is initiated in the ER but completed in the
mitochondria, requiring the exchange of lipid intermediates
between the ER membrane and the mitochondrial outer
membrane at contact sites [54]. ER stress might impair the
synthesis of the intermediates within the ER or disturb con-
tact points required for the exchange of lipid intermediates,
potentially leaving the mitochondria deﬁcient in cardiolipin
which would result in reduced OXPHOS eﬃciency [74].
FinallylossofERhomeostasiscouldimpactthecontribu-
tion of the ER in mitochondrial ﬁssion, a process important
in mitochondrial homeostasis, especially for the eﬃcient
removal of damaged mitochondria by mitophagy. Therefore
αSynuclein-induced ER stress could induce mitochondrial
d y s f u n c t i o ni nam y r i a do fw a y s .
5.6. αSynuclein May InterferewiththeTransport/Distribution/
Disposal of Mitochondria. In the long processes of neurons,
appropriate transport and distribution of mitochondria is
critical to supply both the required high metabolic demands
as well as to sequester excess intracellular Ca2+ to maintain
Ca2+ homeostasis at synapses. In addition to the anterograde
delivery of functional mitochondria, retrograde transport
is required for delivering dysfunctional mitochondria to
the lysosome for mitophagic degradation. Long-range mito-
chondrial transport between the soma and distal axonal and
dendritic regions is reliant on microtubules and associated
motors [75]. Perturbation of microtubule transport would
impair both the appropriate delivery and distribution of
mitochondria within neurons, particularly from the critical
area of the synaptic terminals, as well as the disposal of
potentially ROS producing dysfunctional mitochondria.
Microtubules are dynamic structures, and αSynuclein
may play a role in modulating the polymerisation and
depolymerisation of tubulin. Recombinant GST-αSynuclein
was found to bind tubulin in vitro while the transient
expression of αS y n u c l e i ni nH e L ac e l l sw a sr e p o r t e d
to disrupt microtubule structures [76]. Furthermore, a
dopaminergic cell line exposed to extracellular oligomeric
αSynuclein exhibited decreased tubulin polymerisation. At a
concentration of 250nM, neither monomeric nor oligomeric
αSynuclein aﬀected tubulin polymerisation in vitro. [77].
However, higher molar ratios of αSynuclein to tubulin lead
to a signiﬁcant increase in polymerisation rate, measured
by OD [76], [78]. Strengthening the case for a direct
interaction between αSynuclein and tubulin are multiple
co-IP and in vitro polymerisation experiments utilising
αSynuclein-deletion mutants. These experiments indicate
that only amino acids 61–100 of αSynuclein are required
for observed enhancement of polymerisation. Additionally,
tubulin has been shown to dramatically increase the rate of
αSynuclein ﬁbrilization, measured by Thio-T ﬂuorescence,
suggesting a possible seeding of these ﬁbrils [80]. Contrary
to this apparent enhancement, cells exposed to extracellular
oligomeric αSynuclein and cybrids formed with mitochon-
dria from PD patients both showed increased ratios of free
tubulin to polymerised tubulin, suggesting an inhibition
of polymerisation [10, 77]. Surprisingly, treatment of these
cybrids with taxol, an enhancer of tubulin polymerisation,
restored the free/polymerised tubulin ratio to control lev-
els in PD cybrids with no discernable eﬀect on control
cybrids [10]. Additionally, taxol treatment eliminated high-
molecular-weight αSynuclein oligomers observed in PD, but
not control, cybrids. Also of note, both the A30P and
A53T mutant forms of αSynuclein appeared to inﬂuence
the structure of polymerised tubulin, and the presence of
either mutant in vitro led to amorphous polymers lacking
tubular structure [78]. While the precise mechanism by
whichαSynucleinmayinﬂuencepolymerisationorimproperParkinson’s Disease 7
aggregation of tubulin is not clear, it is apparent that an
interaction between the two proteins exists. Considering the
importance of microtubule tracks for proper distribution
of mitochondria and intracellular transport, it is clear that
perturbation of the microtubule network could signiﬁ-
cantly impact the mitochondrial ﬁssion/fusion cycle and the
mitophagy of ROS-producing mitochondria or lead to ER
stress.
6.PotentialMechanismsby
WhichMitochondrialDysfunctionCould
EnhanceαSynucleinToxicity
6.1. αSynuclein Upregulation by Oxidative Stress Resulting
from Dysfunctional Mitochondria. ROS-producing dysfunc-
tional mitochondria may impact αSynuclein in several ways.
The resulting oxidative stress from dysfunctional mitochon-
drial could cause upregulation of αSynuclein expression
[81]. Given that αSynuclein toxicity is dose dependent, any
increase in αSynuclein expression would be expected to
increase toxicity.
6.2. ER Stress Induced by Mitochondrial Dysfunction. Given
thephysicallyandfunctionallyintimaterelationshipbetween
the ER and mitochondria, mitochondrial dysfunction could
cause ER stress, enhancing ER stress induced by αSynuclein
[33, 70]. This concept is experimentally supported with
compounds that inhibit OXPHOS found to cause ER stress.
The compounds MPP+ and rotenone are both used to
reproduce PD features in model organisms, and in addition
to being mitochondrial complex I inhibitors, they induce
ER stress in cultured neuronal cells [82], [79]. Inhibition
of complex III with antimycin or complex V (ATPase
synthetase) with oligomycin also resulted in ER stress as
judged by the upregulation of ER stress response genes [83,
84]. This induction of the ER stress response is likely due to
a disturbance in mitochondrial Ca2+ buﬀering as either Ca2+
chelation with BAPTA or preventing Ca2+ release from the
oligomycin-treated mitochondria signiﬁcantly suppressed
the ER stress [83]. Mitochondrial dysfunction can trigger a
release of mitochondrial Ca2+ that in turn triggers ER stress.
As the ER is the main store of Ca2+ within the cell, ER stress
results in a further release of Ca2+. Therefore mitochondrial
dysfunction can cause a release of Ca2+ from the cell’s
two largest Ca2+ storage organelles, the mitochondria, and
ER. The resulting signiﬁcant increase in cytosolic Ca2+
levels, derived from both the mitochondria and ER, can
in turn promote αSynuclein oligomerisation/aggregation
[85]. This eﬀect on αSynuclein could potentially create a
viciouscirclethatwouldleadtoincreasedmitochondrialdys-
function and/or increased αSynuclein-dependent ER stress.
Finally, ER stress induced by mitochondrial dysfunction
might in turn impair lipid biosynthesis occurring in the
ER, enhancing sensitivity to toxic species of αSynuclein
[86].
6.3. Mitochondrial Dysfunction Induced Nitric Oxide Produc-
tion and Nitrosative Stress. Mitochondrial dysfunction or ER
stresscouldelevatecytosoliccalciumtolevelscapableofacti-
vating neuronal nitric oxide synthetase (nNOS). The result-
ing nitric oxide (NO) can react with superoxide to produce
the toxic species peroxynitrite. Peroxynitrite can oxidatively
modify proteins, lipids, and nucleic acids resulting in a range
of damages including proteasome inhibition, ER stress, and
mitochondrialdamageincludinginhibitionofcomplexIand
a decrease in mitochondrial membrane potential [87]. NO
and peroxynitrite can decrease glutathione levels, increasing
the cell vulnerability to oxidative stress, but can also cause
either tyrosine nitration or nitrosylation of cysteine residues,
often altering the protein’s function/activity. In PD, proteins
with abnormal S-nitrosylation include Parkin (a ubiquitin
ligase and a familial PD gene), protein disulﬁde isomerase
(PDI, whose impairment causes ER stress), Prx2 (a protein
that protects against oxidative stress in neurons but is
inactivated by S-nitrosylation) [88], and αSynuclein, with
Lewy bodies enriched with the nitrated species [89, 90].
Finally, polymorphisms in neuronal NOS (nNOS) and
inducible NOS (iNOS) are both associated with sporadic PD
[91].
The initiation of autophagy can be impaired by nitric
oxide [92] which raises the possibility that mitochondrial
dysfunction could impair autophagy via the induction of
NOS and resulting nitric oxide production. Impairment of
autophagycouldinturnimpairboththemitophagicdisposal
of dysfunctional mitochondria as well as the autophagic
removal of αSynuclein.
6.4. ROS from Mitochondrial Dysfunction Enhances/Stabilises
αSynuclein Oligomerisation and Increases αSynuclein Toxi-
city. Increases in ROS can also lead to modiﬁcations of
αSynuclein itself. High levels of ROS in the presence of
nitric oxide can lead to the production of reactive nitrogen
species (RNS). Both ROS and RNS can directly modify
αSynuclein at crucial residues; however, RNS may play an
important role in αSynuclein oligomerisation and aggre-
gation. RNS can directly nitrate tyrosine residues, altering
αSynuclein local hydrophobicity and charge. αSynuclein
has four tyrosine residues, one in the lipid-binding and
lysine-rich region of the protein, tyr1, and three clustered
in the C-terminal acidic region, tyr2−4 [93]. Modiﬁcation
of these residues signiﬁcantly alters both the native con-
formation of the protein and its lipid binding dynam-
ics. Nitration at either tyr1 or tyr2−4 leads to a drastic
(∼50%) decrease in binding to small, anionic vesicles.
Interestingly, the A30P mutation shows a similar degree of
membrane aﬃnity loss. This eﬀect could be mimicked for
tyr1 through a tyrosine to aspartic acid targeted mutation,
suggesting an electrostatic basis for the loss of binding.
However,similarmutationstotyr2−4 didnotaltermembrane
binding, indicating a long distance, allosteric basis for
eﬀect of C-terminal nitration on membrane binding [93].
However, nitration does not simply alter the membrane
binding properties of αSynuclein. Nitration also alters the
way in which αSynuclein oligomerises. Native αSynuclein
can easily be induced to form long ﬁbrils via agitation,8 Parkinson’s Disease
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Figure 1: The interrelationship between mitochondrial dysfunction and αSynuclein toxicity. αSynuclein toxicity, directly or indirectly,
impairs mitochondrial function (A). A prominent result of this dysfunction is the production of reactive oxygen species (ROS) which
can be counteracted by the cellular ROS buﬀering systems. However prolonged mitochondrial stress, exacerbated by αSynuclein, has the
potential to deplete this buﬀering capacity, and the resulting increase of cellular ROS has multiple damaging eﬀects such as the modiﬁcation
of αSynuclein (B). Modiﬁed αSynuclein can inhibit chaperone-mediated autophagy (CMA), increasing the proteins toxicity by its ineﬃcient
clearance. αSynuclein toxicity is dose dependant, and excessive amounts of αSynuclein have the potential to block autophagy pathways (i.e.,
macroautophagyandmitophagy).Thisresultsinanaccumulationofdysfunctionalmitochondriaduetoineﬃcientclearance(C).αSynuclein
toxicity can also increase mitochondrial ﬁssion and inhibit mitochondrial fusion (D). Both the increase in mitochondrial fragmentation
and the inability of mitochondria to rejoin the mitochondrial network result in an increase in dysfunctional, depolarised mitochondria.
αSynuclein toxicity also blocks endoplasmic reticulum (ER) to Golgi traﬃcking resulting in ER stress. When under constant and prolonged
stress, the ER releases Ca2+ into the cytosol. Due to mitochondrial-ER contact sites, mitochondria readily buﬀer cytosolic Ca2+;h o w e v e r ,
excess Ca2+ in the mitochondria causes mitochondrial stress (E). Dysfunctional mitochondria in turn release Ca2+ into the cytosol causing
further ER stress. Mitochondrial dysfunction may exacerbate αSynuclein toxicity (F), with both acting synergistically to enhance each other
in a self-amplifying cycle over prolonged periods of time, resulting in multiple downstream eﬀects, including cell death as seen in PD.
incubation at physiological temperatures, and time. How-
ever, nitrated αSynuclein does not form ﬁbrils unless incu-
bated at pH 3. Additionally, the presence of the nitrated
species signiﬁcantly slowed the ﬁbrillation of unmodiﬁed
αSynuclein [93]. While nitration prevented ﬁbrillation, it
accelerated the formation of stabilised oligomers [94].
One proposed mechanism for stabilisation of oligomeric,
modiﬁedαSynucleinisRNS-induceddityrosinecrosslinking.
Crosslinks formed by exposure to peroxynitrate, an RNS,
are extremely stable, remaining intact even after treatment
with 4M urea. Consistent with earlier ﬁndings, crosslinked
αSynuclein does not form ﬁbrils. However, fully formed
ﬁbrils exposed to RNS become likewise crosslinked and
resistant to denaturants [95]. It is likely that the nitrated
αSynuclein detected in intracellular inclusions [93, 94]w a s
modiﬁed after deposition, considering the resistance to
ﬁbrillation exhibited by nitrated αSynuclein.
However, it is still not clear how prevention of ﬁbril
development and stabilisation of small, soluble oligomers
might induce toxicity. One possibility is through the
impairment of chaperone-mediated autophagy (CMA) at
lysosomes. In isolated lysosomes nitrated αSynuclein was
signiﬁcantly impaired in translocating the lysosomal mem-
brane [34]. Accumulation of αSynuclein at the surface of
lysosomes could have deleterious eﬀects on the fusion of
autophagosomes, providing a possible explanation for the
perturbations in the autophagy pathway discussed earlier, as
well as preventing normal CMA-mediated protein turnover.
7. Summary
Itisclearthatnumerouspotentialmechanismsexistinwhich
mitochondrial dysfunction and αSynuclein could interact toParkinson’s Disease 9
exacerbate their neurodegenerative properties (see Figure 1).
In many cases a self-amplifying cycle of mitochondrial
dysfunction or αSynuclein toxicity could be envisaged as
either being the disease-initiating factor yet acting together
during disease progression.
It is important to acknowledge that most in the PD
ﬁeld view mitochondrial dysfunction through the lens of
OXPHOS impairment and increased ROS production, yet
the mitochondria contribute to so many other facets of cell
metabolism including, TCA cycle, NAD+/NADP, and amino
acid biosynthesis, as well as its close relationship in the
function and maintenance of other cellular organelles, with
perturbations in many of these processes potentially also
contributing to PD.
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